- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00230828
Patient-reported Outcomes in the Treatment of Schizophrenia
September 11, 2013 updated by: Solvay Pharmaceuticals
Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials
Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols
Study Overview
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participate in S1543003 and S1543004 in the U.S. sites
Exclusion Criteria:
- Participate in S1543003 and S1543004 other than U.S. sites
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
January 1, 2006
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 30, 2005
First Posted (Estimate)
October 3, 2005
Study Record Updates
Last Update Posted (Estimate)
September 12, 2013
Last Update Submitted That Met QC Criteria
September 11, 2013
Last Verified
September 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S154.3.005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on bifeprunox
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompletedSchizophrenia | Schizoaffective Disorder | Bipolar DisorderUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated
-
Wyeth is now a wholly owned subsidiary of PfizerSolvay PharmaceuticalsCompleted
-
H. Lundbeck A/SSolvay PharmaceuticalsTerminated
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Solvay PharmaceuticalsTerminatedPsychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypeUnited States, Czech Republic, Estonia, Israel, Poland